What is Rosa?
Rosa, operating under the name Rosa and Co, is a specialized firm dedicated to enhancing drug development processes through quantitative mechanistic insights. Leveraging proprietary PhysioPD research platforms, the company collaborates with leading pharmaceutical and biotechnology entities. Rosa provides custom quantitative systems pharmacology models designed to mitigate risks and reduce costs associated with bringing new therapies to market. Their expertise spans a wide array of therapeutic areas, with over two decades of experience in developing mechanistic models that illuminate disease pathways and refine clinical trial strategies. The company also actively contributes to the scientific community through knowledge-sharing webinars.
How much funding has Rosa raised?
Rosa has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Rosa
PPP
Public-Private Partnership
What's next for Rosa?
With a substantial large-scale late-stage funding context, Rosa is poised to accelerate its market penetration and further develop its innovative PhysioPD platforms. The recent strategic investment is likely to fuel advancements in their modeling capabilities, potentially expanding their service offerings to address emerging challenges in precision medicine and personalized therapeutics. Continued collaboration with top-tier pharmaceutical and biotech firms will be crucial for validating and scaling their solutions, solidifying Rosa's role as a key enabler of de-risked and cost-effective drug development.
See full Rosa company page
